<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04029116</url>
  </required_header>
  <id_info>
    <org_study_id>SCY-078-304</org_study_id>
    <nct_id>NCT04029116</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)</brief_title>
  <acronym>CANDLE</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) Compared to Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scynexis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scynexis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to
      evaluate the efficacy and safety of oral ibrexafungerp (formerly &quot;SCY-078&quot;) compared to
      placebo in female subjects 12 years and older with recurrent VVC (RVVC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase 3, multicenter, randomized, double-blind study to evaluate the efficacy
      and safety of oral ibrexafungerp (formerly &quot;SCY-078&quot;) compared to placebo in female subjects
      12 years and older with RVVC. The primary objective of the study is to evaluate the efficacy
      of oral ibrexafungerp in preventing recurrences of VVC in subjects with RVVC based on
      Clinical Success. Approximately 320 subjects are planned to be enrolled into the study. All
      subjects will receive treatment with oral fluconazole for their acute episode present at
      screening. Subjects who respond to fluconazole for their acute episode will be enrolled in
      the prevention of recurrence phase of the study and randomized to ibrexafungerp or placebo.

      Subjects who fail treatment with fluconazole for their acute episode will be included in a
      nested open label Sub-Study, in which they will be offered one-day oral ibrexafungerp for
      their unresolved acute episode.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open label (acute phase treatment) followed by Randomized, Double Blinded phase</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>Week 24</time_frame>
    <description>Efficacy as measured by the percentage of subjects with documented Clinical Success.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects with no Mycologically Proven Recurrence</measure>
    <time_frame>Week 24 and Week 36</time_frame>
    <description>Efficacy as measured by the percentage of subjects with no Mycologically Proven Recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Week 24</time_frame>
    <description>Safety as measured by the number of subjects who discontinue due to treatment related adverse events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Recurrent Vulvovaginal Candidiasis</condition>
  <arm_group>
    <arm_group_label>Ibrexafungerp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Fluconazole 150 mg every 72 hours for 3 doses followed by Oral Ibrexafungerp 300 mg BID (one day) every 4 weeks for a total of 6 dosing days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral Fluconazole 150 mg every 72 hours for 3 doses followed by Oral Placebo BID (one day) every 4 weeks for a total of 6 dosing days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole Tablet</intervention_name>
    <description>150 mg every 72 hours for 3 doses</description>
    <arm_group_label>Ibrexafungerp</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBREXAFUNGERP</intervention_name>
    <description>300 mg BID (one day) every 4 weeks for a total of 6 dosing days</description>
    <arm_group_label>Ibrexafungerp</arm_group_label>
    <other_name>SCY-078</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>BID (one day) every 4 weeks for a total of 6 dosing days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Diagnosis of symptomatic VVC with microscopic examination with KOH positive for yeast
             and normal vaginal pH.

          -  History of 3 or more episodes of VVC in the past 12 months.

          -  Culture confirmation and resolution of the signs and symptoms of the initial VVC
             episode (with treatment).

          -  Able to take oral tablets and capsules.

        Key exclusion Criteria:

          -  Vaginal conditions other than recurrent VVC that may interfere with the diagnosis or
             evaluation of response to therapy.

          -  Recent use of systemic and/or topical vaginal antifungal products.

          -  Pregnant.

          -  History of major system organ disease.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nkechi Azie, MD</last_name>
    <role>Study Director</role>
    <affiliation>Scynexis, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philip Deane</last_name>
    <phone>201 688 2241</phone>
    <phone_ext>2241</phone_ext>
    <email>philip.deane@scynexis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nkechi Azie, MD</last_name>
    <email>Nkechi.azie@scynexis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Precision Trials LLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Sorkin-Wells, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Healthcare Clinical Data Inc</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Chavoustie, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Management</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert I Tydings, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Women Under Study, LLC</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Miller, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center For Women's Health and Wellness LLC</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Eder, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lawrence Obstetrics Gynecology Clinical Research LLC</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven A Sussman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bosque Women's Care</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Swartz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unified Womens CLinical Research</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark E Anderson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unified Women's Clinical Research</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas T Vradelis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>M3 Wake Research, Inc</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pouruchis Bhiwandiwalla, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chattanooga Medical Research Inc</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirk Brody, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Research Center of Memphis, LLC</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B Chappell, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>TMC Life Research Inc</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Jacobs, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 19, 2019</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2019</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrent yeast infection</keyword>
  <keyword>Recurrent yeast vaginitis</keyword>
  <keyword>Chronic yeast vaginitis</keyword>
  <keyword>Ibrexafungerp</keyword>
  <keyword>SCY-078</keyword>
  <keyword>RVVC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Vulvovaginal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

